Más como este
DePuy Synthes se separa de Johnson & Johnson
ESTIMADO71% DE CONFIANZAdentro de 281 díasEl 10-Q de J&J correspondiente al trimestre cerrado el 28 de junio de 2026 fija como objetivo la "finalización en un plazo de 18 a 24 meses tras el anuncio inicial" del 14 de octubre de 2025 (de mediados de abril a mediados de octubre de 2027), y el director financiero Joseph Wolk dijo en julio que J&J "avanza según lo previsto hacia una separación a mediados de 2027" (Bloomberg); "mediados de 2027" se interpreta como la mitad del año, el 1 de julio de 2027, que cae dentro de esa ventana.[1]El negocio de ortopedia de Johnson & Johnson saldrá del grupo como DePuy Synthes —mediante una escisión libre de impuestos o mediante una venta, con Apollo en conversaciones por unos 20.000 millones de dólares— y J&J afirma que la separación va camino de completarse a mediados de 2027.0.79J&J Announces Plan to Spin Off DePuy Synthes
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
CONFIRMADO90% DE CONFIANZAhace 344 díasThe release is datelined "NEW BRUNSWICK, NJ, October 14, 2025 - Johnson & Johnson ... today announced the Company's intent to separate its Orthopaedics business"; it states no time of day (CNBC's[3] report was up at 6:29 a.m. EDT and J&J's X post at 6:40 a.m. EDT), so the pin is the all-day 14 October.Johnson & Johnson said it would separate its roughly $9.2 billion-a-year orthopaedics business into a standalone company called DePuy Synthes within 18 to 24 months, and named former Smith & Nephew chief Namal Nawana to run it.0.73J&J Completes Its $1 Billion Acquisition of Firefly Bio
CONFIRMADO87% DE CONFIANZAhace 56 días"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.$1B0.63J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
CONFIRMADO82% DE CONFIANZAhace 58 díasJ&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.61Abbott Agrees to Buy Exact Sciences for $21 Billion
CONFIRMADO86% DE CONFIANZAhace 307 díasThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".[1]Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.$21B0.60La Estación Espacial Internacional, destinada a un reingreso controlado
PROGRAMADO77% DE CONFIANZAdentro de 4,3 añosIndicado como previsto, según la fuente: «La NASA[3] y sus socios internacionales planean desorbitar intencionadamente el laboratorio orbital hacia 2030 o poco después».La NASA planea retirar la ISS, de 25 años, dirigiéndola hacia una zona remota del Pacífico Sur mediante un vehículo de desorbitación de SpaceX construido para ese fin.$843M0.59Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
CONFIRMADO87% DE CONFIANZAhace 120 díasLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".[1]Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.$3.8B0.58Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion
CONFIRMADO88% DE CONFIANZAhace 23 díasThe release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".[1]Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.$2.9B0.58Inside Tesla's $5 Billion Gigafactory - Visual Capitalist
The $5 Billion Tesla Gigfactory will set a new precedent for economies of scale in battery production, creating demand for graphite, cobalt, and lithium. The name gigafactory comes from the plant's planned annual battery production capacity of 35 gigawatt-hours, which Tesla said on Wednesday it would achieve by 2018.$5B0.58Huang: $1 trillion in Blackwell and Vera Rubin orders through 2027
CONFIRMADO90% DE CONFIANZAhace 191 díasCNBC's[1] 16 March 2026 coverage of the GTC 2026 keynote reports the remark.At GTC 2026, Huang said he expects purchase orders for Blackwell and Vera Rubin to reach $1 trillion through 2027, up from the $500 billion outlook given the previous year.0.58Babcock & Wilcox Gets Go-Ahead on $2.4B Base Electron Power Plant
CONFIRMADO87% DE CONFIANZAhace 203 díasStated as done, per babcock.com[1]: "(AKRON, Ohio - March 4, 2026) - Babcock & Wilcox ... announced today that it has received full notice to proceed on a $2.4 billion design-build agreement"; the Business Wire copy on Yahoo Finance is timestamped 11:30 UTC.Babcock & Wilcox received full notice to proceed on a $2.4 billion design-build contract with Base Electron, an Applied Digital-backed power producer, for 1.2 GW of gas-fired boiler and steam turbine capacity to supply Applied Digital AI Factory campuses.$2.4B0.58Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
CONFIRMADO87% DE CONFIANZAhace 176 díasThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".[1]Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.$7.8B0.58
